Swine Respiratory Disease Treatment Market – Global Trends, 2017 – 2025

Swine respiratory disease affects the respiratory tract of swine. It is one of the prevalent cause of death in nursery pigs and grower/finisher pigs. There are multiple pathogens, viruses, and other secondary causative agents that causes respiratory disease in swine. Primary pathogens that causes swine respiratory disease are Actinobacillus pleuropneumoniae (APP), Mycoplasma hyopneumoniae, Bordetella bronchiseptica, and Pasteurella multocida. Viral agents involved are porcine reproductive and respiratory syndrome (PRRS) virus and swine influenza virus (SIV). Various diseases that come under ambit of swine respiratory disease are mycoplasma pneumonia, swine influenza, classical swine fever atrophic rhinitis, pleuropneumonia, porcine reproductive and respiratory syndrome, and porcine circovirus type 2. These infectious agents together increase the severity of the disease.

Access Table of Content (TOC) Of the Report: https://www.coherentmarketinsights.com/ongoing-insight/toc/1274

China, U.S., and E.U to drive growth of the swine respiratory disease treatment market due to high pork production

According to the factsheet by United Nations Food and Agriculture Organization (UN-FAO) worldwide there is close to one billion headcount of swine. China has highest number of headcount, followed by the U.S. and EU. These regions are expected to drive growth of the respiratory disease treatment market, owing to high pork production. As per the United States Department of Agriculture (USDA), around 108.2 million metric tons of pork was produced in 2016, which requires supply of healthy swine. Early vaccination is essential for healthy swine as respiratory disease in swine leads to lung damage, poor growth of swine, medication cost, and in turn results into lower economic efficiency for swine farmer. Therefore many of these regions opt for vaccination to prevent the respiratory disease in swine, which in turn is expected to propel growth for the swine respiratory disease treatment market. According to the study published in Virology Journal in 2017, emergence of porcine cyclovirus type 3 in pigs in regions such as China, U.S. and some part of Europe is fueling growth of the swine respiratory disease treatment market. According to Scientific Reports published in 2013, porcine reproductive and respiratory syndrome is economically most important disease of swine in North America, Europe, and Asia. North America spends around US$ 600 million annually for treatment of this disease.

However, increasing inclination of population towards adoption of vegetarian diet in China leading to lower swine farming prospect is restating growth of the swine respiratory treatment market. Also, according to the United States Department of Agriculture (USDA) cost of pork was dropping till end of 2017, which negatively affects the swine farming.

Key players operating in the swine respiratory disease treatment market include Zoetis, Inc. Merck Animal Health, Bayer AG, Boehringer Ingelheim Vetmedica, Inc., Elanco Animal Health, Virbac Group, Norbrook, Ceva Santé Animale, Vetoquinol, Bimeda holdings PLC, and Agrilabs, Inc. In January 2018, FDA approved dose of 100 gram per ton feed for Lincomix (Product from Zoetis, Inc.), which contains lincomycin hydrochloride to reduce the severity of swine respiratory disease from mycoplasma hyopneumoniae.

Click here to know more about this report: https://www.coherentmarketinsights.com/ongoing-insight/swine-respiratory-disease-treatment-market-1274

Lincomix is the only feed medication approved against mycoplasma hyopneumoniae, which is leading cause for swine pneumonia. In 2016, Gamithromycin (ZACTRAN) was approved for use in pigs by USDA. In June 2017, a team of researchers from University of Leicester isolated 20 bacteriophages that targets 72 potential drug resistant bacteria in pigs. This bacteriophages were found to be more specific for treatment of bacterial infections in pigs. MSD Animal Health (known as Merck Animal Health in the U.S. and Canada) in November 2017, signed an agreement to acquire Vilsan Pharmaceuticals which is a division of Vimar Group, based in Turkey. Vilsan Pharmaceuticals holds significant share in animal health products in Turkey.

You may be interested

Uterine Fibroid Treatment Is Expected To Witness Significant Growth In Near Future Due To Growing Healthcare Awareness Within The Population In Economies
Business
Business

Uterine Fibroid Treatment Is Expected To Witness Significant Growth In Near Future Due To Growing Healthcare Awareness Within The Population In Economies

Mohit Joshi - October 22, 2018

Coherent Market Insights released a new market study on 2018-2026 Uterine Fibroid Treatment Devices Market with 100+ market data Tables, Pie Chat, Graphs & Figures spread through…

Metastatic Osteosarcoma Treatment Market Growing at Steady CAGR to 2026
Business
Business

Metastatic Osteosarcoma Treatment Market Growing at Steady CAGR to 2026

Mohit Joshi - October 22, 2018

The Metastatic Osteosarcoma Treatment Market is expected to have a highly positive outlook for the next eight years 2018-2026 according to a recently released Metastatic Osteosarcoma Treatment Market research report. The…

Structural Heart Devices Market to receive overwhelming hike in Revenues by 2026
Business
Business

Structural Heart Devices Market to receive overwhelming hike in Revenues by 2026

Mohit Joshi - October 22, 2018

The Structural Heart Devices Market is expected to have a highly positive outlook for the next eight years 2018-2026 according to a recently released Structural Heart Devices Market research report. The…

Most from this category